NR3C2 and type 2 diabetes mellitus: The KDIGO 2024 guidelines state the following: “We suggest a nonsteroidal mineralocorticoid receptor antagonist with proven kidney or cardiovascular benefit for adults with type 2 diabetes (T2D), an eGFR > 25 mL/min per 1.73 m2, normal serum potassium concentration, and albuminuria (>30 mg/g [>3 mg/mmol]) despite maximum tolerated dose of RAS inhibitor (RASi)” [37].